Chemotherapy News and Research

Latest Chemotherapy News and Research

Research reveals that 21% of death claims are rejected by California's largest private insurers

More than one of every five requests for medical claims for insured patients, even when recommended by a patient's physician, are rejected by California's largest private insurers, amounting to very real death panels in practice daily in the nation's biggest state, according to data released today by the California Nurses Association/National Nurses Organizing Committee.

3 Sep 2009

Yale University awarded $36 million ARRA funds for over 100 research projects

Faculty at Yale University have been awarded over 100 research grants totaling $36 million since February 2009, when the federal stimulus package was signed into law. Known as the American Recovery and Revitalization Act of 2009 (ARRA), the law aims to reinvigorate the economy and lay the foundation for long-term economic recovery by increasing investments in infrastructure, education, the environment and scientific research.

3 Sep 2009

Avastin increases survival rates in recurrent glioblastoma affected patients

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.

3 Sep 2009

New target for cancer cure identified

Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.

3 Sep 2009

Colorado braces for mental health cuts, Florida nursing homes brace for Medicare cuts, and other developments

Kaiser Health News: "Three years after Massachusetts implemented a state program to provide near universal health care, officials said that a key to their success was that stakeholders from the state's health care sector and the business community had a commitment to implementing the program." Despite successes, one state official said cost containment remains a challenge (Marcy, 9/1).

3 Sep 2009

Hope for limiting skin toxicity of cancer drug users

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.

2 Sep 2009

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy.

2 Sep 2009

Patient perception of physician disclosure key to gaining trust

When reporting medical errors, patients' perceptions of their physicians' disclosure may be key to gaining their trust, according to researchers from the Johns Hopkins Bloomberg School of Public Health. However, a positive perception of the disclosure has little effect on the lawsuit risk a physician faces.

2 Sep 2009

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

2 Sep 2009

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance. A "death receptor" can possibly provide information as to how great the chances of success are for chemotherapy. At the same time, it offers a new approach for promising brain tumor therapy.

2 Sep 2009

Oncolytics Biotech obtains 32nd U.S. Patent grant

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 32nd U.S. Patent, # 7,582,289, entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods of using modified parapoxvirus orf virus to treat Ras-mediated cancers.

1 Sep 2009

St. Baldrick’s Foundation to organize fund raiser for childhood cancer research

Dozens of men, women and children are expected to shave their heads bald to show solidarity to children with cancer and to raise money for childhood cancer research September 19, 2009 at 5:00 at The Friendly Sons of the Shillelagh Club in West Orange, NJ.

1 Sep 2009

InfuSystem Holdings appoints Board Chairman as new Chief Executive Officer

InfuSystem Holdings, Inc., announced today that its Board of Directors has accepted the resignation of Mr. Steve Watkins as President, Chief Executive Officer and Board Member, effective September 7, 2009. Sean McDevitt, Chairman of the Board, will immediately take over the additional role of Chief Executive Officer.

1 Sep 2009

Natural food compounds may play a vital role in cancer treatment

Research in the Linus Pauling Institute at Oregon State University suggests that some natural food compounds, which previously have been studied for their ability to prevent cancer, may be able to play a more significant role in treating it - working side-by-side with the conventional drugs that are now used in chemotherapy.

1 Sep 2009

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

A study in the Sept.1 issue of the journal Sleep shows that the sleep-wake activity rhythms of breast cancer patients are impaired during the administration of chemotherapy. Results indicate that the first cycle of chemotherapy is associated with a temporary disruption of these rhythms, while repeated administration of chemotherapy results in progressively worse and more enduring impairments.

1 Sep 2009

MabCure featured in the August edition of Biotechnology Focus magazine

MabCure, Inc. (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in the August edition of Biotechnology Focus, Canada's oldest and most successful magazine serving the Canadian life science industry.

31 Aug 2009

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Peregrine Pharmaceuticals, Inc., today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program.

31 Aug 2009

Doxorubicin granted orphan drug designation by the FDA

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the U.S. Food & Drug Administration granted Delcath's request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer. Clinicians in the U.S. diagnose nearly 20,000 cases of HCC annually.

31 Aug 2009

Research reveals the reason why some patients with Ewing's sarcoma do not respond to chemotherapy

31 Aug 2009

New radiotherapy treatment devised for treating women with metastatic ovarian cancer

In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. An initial study in patients conducted jointly by the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital has found that the treatment has no unwanted side-effects.

31 Aug 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Research reveals that 21% of death claims are rejected by California's largest private insurers

Yale University awarded $36 million ARRA funds for over 100 research projects

Avastin increases survival rates in recurrent glioblastoma affected patients

New target for cancer cure identified

Colorado braces for mental health cuts, Florida nursing homes brace for Medicare cuts, and other developments

Hope for limiting skin toxicity of cancer drug users

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Patient perception of physician disclosure key to gaining trust

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Oncolytics Biotech obtains 32nd U.S. Patent grant

St. Baldrick’s Foundation to organize fund raiser for childhood cancer research

InfuSystem Holdings appoints Board Chairman as new Chief Executive Officer

Natural food compounds may play a vital role in cancer treatment

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

MabCure featured in the August edition of Biotechnology Focus magazine

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Doxorubicin granted orphan drug designation by the FDA

Research reveals the reason why some patients with Ewing's sarcoma do not respond to chemotherapy

New radiotherapy treatment devised for treating women with metastatic ovarian cancer

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in